认识和联系Profil的专家

简介

Grit作为医生在德国和哥斯达黎加的不同的医学领域任职过，例如外科、一般内科、神经学科。1999年她参与了一项III期国际临床研究并开始了她在临床研究方面的工作经历。她在早期临床研究方面工作了12年并于2013年加入了Profil。她是临床药理学资格委员会认证的医学专家，作为临床药理学总监，她负责为Profil的医生开展临床药理学专业课程。

发表物

以下是Grit的近期发表物: 

• Andersen G, Meiffren G, Famulla S, Heise T, Ranson A, Seroussi C, Eloy R, Gaudier M, Charvet R, Chan Y-P, Soula O, DeVries JH.
  ADO09, a co-formulation of the amylin-analog pramlintide and the insulin analog A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes (T1D).
  DIABETES OBES METAB 2020 Dec 18. doi: 10.1111/dom.14302. Online ahead of print.
• Bergougnan L, Andersen G, Plum-Mörschel L, Evaristi MF, Poirier B, Tardat A, Ermer M, Herbrand T, Arrubla J, Coester HV, Sansone R, Heiss C, Vitse O, Hurbin F, Boiron R, Benain X, Radzik D, Janiak P, Muslin AJ, Hovsepian L, Kirkesseli S, Deutsch P, Parkar AA. Endothelial-protective effects of a G-protein-biased sphingosine-1 phosphate receptor-1 agonist, SAR247799, in type-2 diabetes rats and a randomized placebo-controlled patient trial. Br J Clin Pharmacol 2020 Oct 30. doi: 10.1111/bcp.14632. Online ahead of print
• Andersen G, Plum-Mörschel L, Hockings PD, Morsing A, Palle MS, Svolgaard O, Flint A.
  Clinical characteristics of a non-alcoholic fatty liver disease population across the fibrosis spectrum measured by magnetic resonance elastography: Analysis of screening data.
  Adv Ther 2020 Oct 1. doi: 10.1007/s12325-020-01503-x. Online ahead of print
• Meiffren G, Andersen G, Eloy R, Seroussi C, Mégret C, Famulla S, Chan YP, Gaudier M, Soula O, DeVries H, Heise T.
  ADO09, a Coformulation of Pramlintide (PRAM) and Insulin A21G, Improves Postprandial Glucose vs. Novolog in Type 1 Diabetes (T1D)”
  Diabetes 69 2020 June 9. (Supplement 1)
• Zijlstra E, Andersen G, Plum-Moerschel L, Rhodes M, Patton R, Bueche B, Kuo MC, Truc H, LE, Stedmann BJ, Platton, JS 
  Variability of 501 Inhaled Insulin Absorption and Action
  Diabetes 69 2020 June 9. (Supplement 1)
• Leohr J, Dellva MA, Coutant DE, LaBell E, Heise T, Andersen G, Zijlstra E, Hermanski L, Nosek L, Linnebjerg H.
  Pharmacokinetics and glucodynamics of ultra rapid lispro (URLi) versus Humalog (lispro) in patients with type 2 diabetes mellitus: A phase I randomised, crossover study.
  Clin Pharmacokinet 2020 May 29. doi: 10.1007/s40262-020-00901-2. Online ahead of print
• Meiffren G, Seroussi C, Ranson A, Charvet R, Gaudier M, Andersen G, Zijlstra E, DeVries H, Heise T, Soula R, Soula O.
  BioChaperone Pramlintide Insulin (BCPramIns), a New Co-Formulation of Pramlintide (PRAM) and Human Insulin (INS), Improves Postprandial Blood Glucose (BG) vs. Both Separate Injections of PRAM+INS and Insulin Lispro (LIS) in Subjects with T1D
  Diabetes 68 2019 June 4. (Supplement 1)
• Andersen G, Meiffren G, Lamers D, DeVries JH, Ranson A, Seroussi C, Alluis B, Gaudier M, Soula O, Heise T.
  Ultra-rapid BioChaperone Lispro improves post-prandial blood glucose excursions versus insulin lispro in a 14-day crossover treatment study in patients with type 1 diabetes.
  DIABETES OBES METAB 20: 2627-2632, 2018
• Meiffren G, Plum-Moerschel L, Ranson A, Anastassiadis E, Seroussi C,  Correia J, Andersen G,  Gaudier M, Soula O, Glezer S, Alluis B.
  BioChaperone 222 (BC222), the New Excipient Enabling the Ultra-rapid BioChaperone Lispro (BCLIS) Formulation, Is Completely Absorbed and Rapidly Excreted after Subcutaneous (s.c.) Injection 
  Diabetes 67 2018 June 22. (Supplement 1)
• Moschetti V, Kim M, Sand M, Wunderlich G, Andersen G, Feifel U, Jang IJ, Timmer W, Rosenbrock H, Boland K.
  The safety, tolerability and pharmacokinetics of BI 409306, a novel and potent PDE9 inhibitor: Overview of three Phase I randomised trials in healthy volunteers
  European Neuropsychopharmacology 28 (5), Pages 643-655, 2018
• Andersen G, Meiffren G, Alluis B, Ranson A, Soula R, Gaudier M, Soula O, Kazda C, Heise T, Bruce S.
  Ultra-rapid BioChaperone Lispro ameliorates postprandial blood glucose (PPBG) in a group with diabetes mellitus
  Diabetologie und Stoffwechsel 12 (S 01), Pages 1-84, 2017
• Forst T, Falk A, Andersen G, Fischer A, Weber MM, Voswinkel S, Heise T, Kapitza C, Plum-Mörschel L.
  Effects on alpha- and beta-cell function of sequentially adding empagliflozin and linagliptin to therapy in people with type 2 diabetes previously receiving metformin: An exploratory mechanistic study.
  DIABETES OBES METAB 19: 489-495, 2017
• Zhaoyang L, Hard ML, Andersen G, Pabst G, Wagener G, Singh T, Chin W, Culm-Merdek K, Boltje I, von Moltke LL.
  Pharmacokinetics, safety and tolerability of mipomersen in healthy Japanese volunteers and comparison with Western subjects 
  International journal of clinical pharmacology and therapeutics 52(4): 314-20, 2014

浏览xxxxx的全部发表物列表或浏览Profil近期的发表物列表，以查看我们的其他发表物。

主要成就及工作经验